166 related articles for article (PubMed ID: 16357522)
21. Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer.
Nemunaitis J; Dillman RO; Schwarzenberger PO; Senzer N; Cunningham C; Cutler J; Tong A; Kumar P; Pappen B; Hamilton C; DeVol E; Maples PB; Liu L; Chamberlin T; Shawler DL; Fakhrai H
J Clin Oncol; 2006 Oct; 24(29):4721-30. PubMed ID: 16966690
[TBL] [Abstract][Full Text] [Related]
22. Chronic vaccination with a therapeutic EGF-based cancer vaccine: a review of patients receiving long lasting treatment.
Gonzalez G; Crombet T; Lage A
Curr Cancer Drug Targets; 2011 Jan; 11(1):103-10. PubMed ID: 21062240
[TBL] [Abstract][Full Text] [Related]
23. Effect of blockade of the EGF system on wound healing in patients vaccinated with CIMAvax® EGF.
Fernández Lorente A; Acosta Brooks S; Neninger Vinageras E; Barroso Alvarez Mdel C; Wilkinson Brito B; Troche Concepción M; Martínez Pérez LB; Viada González CE; Crespo Diaz T; Casacó Parada AR
World J Surg Oncol; 2013 Oct; 11():275. PubMed ID: 24127898
[TBL] [Abstract][Full Text] [Related]
24. Using immunotherapy to target EGF in patients with NSCLC.
O'Mahony D; Dennis PA
Cancer Biol Ther; 2006 Feb; 5(2):150-1. PubMed ID: 16552172
[No Abstract] [Full Text] [Related]
25. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
26. [Research Advances in CIMAvax-EGF for Non-small-cell Lung Cancer].
Zhang JY; Zhu L; Yang HK; Chen F
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2018 Jun; 40(3):411-414. PubMed ID: 29978802
[TBL] [Abstract][Full Text] [Related]
27. A Novel Combined Conjugate Therapeutic Cancer Vaccine, Recombinant EGF-CRM197, in Patients With Advanced Solid Tumors: A Phase I Clinical Study.
Xiong AW; Fang JM; Ren SX; Li W; Wang J; Zhao Y; Chen GY; Xu Q; Zhou CC
Front Oncol; 2021; 11():745699. PubMed ID: 34804932
[TBL] [Abstract][Full Text] [Related]
28. A phase II trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer patients vaccinated with an hTERT cryptic peptide.
Kotsakis A; Papadimitraki E; Vetsika EK; Aggouraki D; Dermitzaki EK; Hatzidaki D; Kentepozidis N; Mavroudis D; Georgoulias V
Lung Cancer; 2014 Oct; 86(1):59-66. PubMed ID: 25130084
[TBL] [Abstract][Full Text] [Related]
29. Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine.
MacLean GD; Reddish MA; Koganty RR; Longenecker BM
J Immunother Emphasis Tumor Immunol; 1996 Jan; 19(1):59-68. PubMed ID: 8859725
[TBL] [Abstract][Full Text] [Related]
30. Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF; Kyte JA; Kersten C; Sundstrøm S; Møller M; Nyakas M; Hansen GL; Gaudernack G; Aamdal S
Clin Cancer Res; 2011 Nov; 17(21):6847-57. PubMed ID: 21918169
[TBL] [Abstract][Full Text] [Related]
31. Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients.
Rodriguez PC; Neninger E; García B; Popa X; Viada C; Luaces P; González G; Lage A; Montero E; Crombet T
J Immune Based Ther Vaccines; 2011 Oct; 9():7. PubMed ID: 22024351
[TBL] [Abstract][Full Text] [Related]
32. Personalized peptide vaccination in patients with refractory non-small cell lung cancer.
Yoshiyama K; Terazaki Y; Matsueda S; Shichijo S; Noguchi M; Yamada A; Mine T; Ioji T; Itoh K; Shirouzu K; Sasada T; Takamori S
Int J Oncol; 2012 May; 40(5):1492-500. PubMed ID: 22307435
[TBL] [Abstract][Full Text] [Related]
33. Safety, Immunogenicity, and 1-Year Efficacy of Universal Cancer Peptide-Based Vaccine in Patients With Refractory Advanced Non-Small-Cell Lung Cancer: A Phase Ib/Phase IIa De-Escalation Study.
Adotévi O; Vernerey D; Jacoulet P; Meurisse A; Laheurte C; Almotlak H; Jacquin M; Kaulek V; Boullerot L; Malfroy M; Orillard E; Eberst G; Lagrange A; Favier L; Gainet-Brun M; Doucet L; Teixeira L; Ghrieb Z; Clairet AL; Guillaume Y; Kroemer M; Hocquet D; Moltenis M; Limat S; Quoix E; Mascaux C; Debieuvre D; Fagnoni-Legat C; Borg C; Westeel V
J Clin Oncol; 2023 Jan; 41(2):373-384. PubMed ID: 36070539
[TBL] [Abstract][Full Text] [Related]
34. Vaccines for the treatment of non-small cell lung cancer: a renewed anticancer strategy.
Gridelli C; Rossi A; Maione P; Ferrara ML; Castaldo V; Sacco PC
Oncologist; 2009 Sep; 14(9):909-20. PubMed ID: 19726457
[TBL] [Abstract][Full Text] [Related]
35. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
[TBL] [Abstract][Full Text] [Related]
36. Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer.
Raez LE; Cassileth PA; Schlesselman JJ; Sridhar K; Padmanabhan S; Fisher EZ; Baldie PA; Podack ER
J Clin Oncol; 2004 Jul; 22(14):2800-7. PubMed ID: 15254047
[TBL] [Abstract][Full Text] [Related]
37. Active immunotherapy for non-small-cell lung cancer: moving toward a reality.
Perez CA; Santos ES; Raez LE
Expert Rev Anticancer Ther; 2011 Oct; 11(10):1599-605. PubMed ID: 21999133
[TBL] [Abstract][Full Text] [Related]
38. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M
J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic vaccines explored in patients with non-small cell lung cancer.
Ma K; Tang YH
Anticancer Agents Med Chem; 2014 Feb; 14(2):256-64. PubMed ID: 24237217
[TBL] [Abstract][Full Text] [Related]
40. Beyond the standard of care: a review of novel immunotherapy trials for the treatment of lung cancer.
Hall RD; Gray JE; Chiappori AA
Cancer Control; 2013 Jan; 20(1):22-31. PubMed ID: 23302904
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]